93102-89-7

Upstream product

• 81167-39-7 methyl N-(diphenylmethylene)glycinate 
• 403-43-0 4-fluorobenzoyl chloride 
• 1422175-44-7 3-(4-fluorophenyl)-2-hydroxyimino-3-oxo-propionic acid methyl ester 
• 63131-29-3 methyl 4-fluorobenzoyl acetate 
• 89204-90-0 5-(4-Fluoro-phenyl)-oxazole-4-carboxylic acid methyl ester 

Downstream Products

• 93103-04-9 5-(4-fluorophenyl)-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid methyl ester 
• 1422175-45-8 5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazole-4-carboxylic acid methyl ester 
• 1422175-46-9 C₁₂H₁₁FN₂O₃S 
• 1422175-97-0 C₂₅H₂₂FN₅O₅S 
• 1422175-98-1 C₂₈H₂₄FN₇O₃S 
• 1422175-21-0 5-(4-fluorophenyl)-2-methylsulfinyl-1H-imidazole-4-carboxylic acid 
• 1422175-20-9 5-(4-fluorophenyl)-2-methylthio-1H-imidazole-4-carboxylic acid 
• 1422175-47-0 5-(4-fluorophenyl)-2-methanesulfonyl-1H-imidazole-4-carboxylic acid methyl ester 
• 1422175-22-1 5-(4-fluorophenyl)-2-methanesulfonyl-1H-imidazole-4-carboxylic acid 
• 1422175-71-0 C₂₇H₂₂FN₇O₃S 
• 1422175-70-9 C₂₇H₂₃FN₆O₄S 
• 1422175-72-1 C₂₄H₂₀FN₅O₅S 
• 1422175-73-2 C₂₇H₂₂FN₇OS 
• 1422175-83-4 C₂₄H₂₀FN₅O₃S 

Relevant academic research and scientific papers

Rhodium-mediated asymmetric transfer hydrogenation: A diastereo- and enantioselective synthesis of: Syn -α-amido β-hydroxy esters

The preparation of syn α-benzoylamido β-hydroxy esters through asymmetric transfer hydrogenation (ATH) with a tethered Rh(iii)-DPEN complex via dynamic kinetic resolution (DKR) has been developed for the first time starting from α-benzoylamido β-keto esters. A variety of α-benzoylamido β-keto esters were converted under mild conditions into the corresponding syn α-benzoylamino β-hydroxy esters with high yields (up to 98%) and diastereomeric ratios (up to >99:1 dr) as well as excellent enantioselectivities (up to >99% ee).

PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS

The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.